Computational design of ligand-binding proteins with high affinity and selectivity

The ability to design proteins with high affinity and selectivity for any given small molecule is a rigorous test of our understanding of the physiochemical principles that govern molecular recognition. Attempts to rationally design ligand-binding proteins have met with little success, however, and the computational design of protein–small-molecule interfaces remains an unsolved problem. Current approaches for designing ligand-binding proteins for medical and biotechnological uses rely on raising antibodies against a target antigen in immunized animals and/or performing laboratory-directed evolution of proteins with an existing low affinity for the desired ligand, neither of which allows complete control over the interactions involved in binding. Here we describe a general computational method for designing pre-organized and shape complementary small-molecule-binding sites, and use it to generate protein binders to the steroid digoxigenin (DIG). Of seventeen experimentally characterized designs, two bind DIG; the model of the higher affinity binder has the most energetically favourable and pre-organized interface in the design set. A comprehensive binding-fitness landscape of this design, generated by library selections and deep sequencing, was used to optimize its binding affinity to a picomolar level, and X-ray co-crystal structures of two variants show atomic-level agreement with the corresponding computational models. The optimized binder is selective for DIG over the related steroids digitoxigenin, progesterone and β-oestradiol, and this steroid binding preference can be reprogrammed by manipulation of explicitly designed hydrogen-bonding interactions. The computational design method presented here should enable the development of a new generation of biosensors, therapeutics and diagnostics.

[1]  B. Shilton,et al.  Structural studies of an engineered zinc biosensor reveal an unanticipated mode of zinc binding. , 2005, Journal of molecular biology.

[2]  Eric A. Althoff,et al.  De Novo Computational Design of Retro-Aldol Enzymes , 2008, Science.

[3]  David Baker,et al.  Structural analyses of covalent enzyme-substrate analog complexes reveal strengths and limitations of de novo enzyme design. , 2011, Journal of molecular biology.

[4]  Birte Höcker,et al.  Computational design of ligand binding is not a solved problem , 2009, Proceedings of the National Academy of Sciences.

[5]  D. Baker,et al.  Restricted sidechain plasticity in the structures of native proteins and complexes , 2011, Protein science : a publication of the Protein Society.

[6]  Jasmine L. Gallaher,et al.  Computational Design of an Enzyme Catalyst for a Stereoselective Bimolecular Diels-Alder Reaction , 2010, Science.

[7]  Eric A. Althoff,et al.  Kemp elimination catalysts by computational enzyme design , 2008, Nature.

[8]  Colin W. Taylor,et al.  Analysis of protein-ligand interactions by fluorescence polarization , 2011, Nature Protocols.

[9]  John McCafferty,et al.  Beyond natural antibodies: the power of in vitro display technologies , 2011, Nature Biotechnology.

[10]  D. Baker,et al.  Role of conformational sampling in computing mutation‐induced changes in protein structure and stability , 2011, Proteins.

[11]  D. Baker,et al.  Native protein sequences are close to optimal for their structures. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[13]  Jens Meiler,et al.  New algorithms and an in silico benchmark for computational enzyme design , 2006, Protein science : a publication of the Protein Society.

[14]  D. Baker,et al.  High Resolution Mapping of Protein Sequence–Function Relationships , 2010, Nature Methods.

[15]  G. Brett,et al.  Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands. , 2000, Pharmacological reviews.

[16]  A. Fersht,et al.  Hydrogen bonding and biological specificity analysed by protein engineering , 1985, Nature.

[17]  R. Nussinov,et al.  The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.

[18]  David Baker,et al.  Role of the Biomolecular Energy Gap in Protein Design, Structure, and Evolution , 2012, Cell.

[19]  Sarel J Fleishman,et al.  Emerging themes in the computational design of novel enzymes and protein–protein interfaces , 2013, FEBS letters.

[20]  K Dane Wittrup,et al.  Isolating and engineering human antibodies using yeast surface display , 2006, Nature Protocols.

[21]  Adrien Treuille,et al.  Predicting protein structures with a multiplayer online game , 2010, Nature.

[22]  Douglas M. Fowler,et al.  Enrich: software for analysis of protein function by enrichment and depletion of variants , 2011, Bioinform..

[23]  David Baker,et al.  An exciting but challenging road ahead for computational enzyme design , 2010, Protein science : a publication of the Protein Society.

[24]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[25]  David Baker,et al.  Bridging the gaps in design methodologies by evolutionary optimization of the stability and proficiency of designed Kemp eliminase KE59 , 2012, Proceedings of the National Academy of Sciences.

[26]  A. Wand,et al.  Conformational entropy in molecular recognition by proteins , 2007, Nature.

[27]  Jens Meiler,et al.  RosettaScripts: A Scripting Language Interface to the Rosetta Macromolecular Modeling Suite , 2011, PloS one.

[28]  T. Kosten,et al.  Vaccines Against Drug Abuse , 2012, Clinical pharmacology and therapeutics.

[29]  L. Benatuil,et al.  An improved yeast transformation method for the generation of very large human antibody libraries. , 2010, Protein engineering, design & selection : PEDS.

[30]  G. Georgiou,et al.  Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS) , 2001, Nature Biotechnology.

[31]  F. Arnold,et al.  Optimizing non-natural protein function with directed evolution. , 2011, Current opinion in chemical biology.

[32]  Timothy A. Whitehead,et al.  Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing , 2012, Nature Biotechnology.

[33]  David Baker,et al.  De Novo Enzyme Design Using Rosetta3 , 2011, PloS one.

[34]  H. Wolfson,et al.  Shape complementarity at protein–protein interfaces , 1994, Biopolymers.

[35]  E. Haber,et al.  High-affinity monoclonal antibodies to the cardiac glycoside, digoxin. , 1982, Journal of immunology.

[36]  F. J. Poelwijk,et al.  The spatial architecture of protein function and adaptation , 2012, Nature.